Ekachai Medical Care vs Fresenius Medical Care AG & Co. KGaA: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Ekachai Medical Care Public Company Limited (EKH.BK)

Q3 202614 Aug – 9 Oct 2026

▲4

EKH expands specialty hospitals as Q2 profit jumps 28%

Q2 profit surges 28% on higher patient volumes EKH's Q2 2026 net profit rose 27.88% to 60.18 million baht, with revenue up 22.35% to 342.88 million baht. Growth came from more patients at Khun Hospital Rama 2, the heart center, and the IVF fertility unit, helped by returning Chinese clients. This shows the core business is healthy and supports the stock price.
This is the key earnings result that shows EKH's core business is growing strongly.
New specialty hospitals to drive future revenue EKH is building three new projects: Khun Wattanapat (elderly care), Bloom Hospital (mental health), and a wellness center. Bloom opened in September with 400 million baht invested, targeting 50 million baht first-year revenue. These expand EKH's revenue base and support long-term growth, pushing the stock up.
These new projects are the main growth drivers that will add revenue from Q3 2026 onward.
Q3 patient volumes rise on seasonal outbreaks EKH reported Q3 2026 patient numbers grew, with bed occupancy at 50-70%, helped by COVID-19 and flu outbreaks and volatile weather. The company expects second-half results to beat the first half and maintains double-digit full-year revenue growth. This supports the stock price.
This shows the positive trend continuing into Q3, confirming the growth story.
Brokerage sets 5.85 baht target, sees recovery Yuanta Securities maintained a Trading recommendation with a 5.85 baht target after visiting Bloom Hospital. It expects 2026 profit of 248 million baht and dividend yields of 5.5-6.1%, with a clear recovery in 2027. This gives investors confidence and can lift the stock.
Analyst coverage with a target price and dividend yield provides a valuation anchor for investors.

September 202614 Aug – 9 Oct 2026

▲4

EKH expands specialty hospitals as Q2 profit jumps 28%

Q2 profit surges 28% on higher patient volumes EKH's Q2 2026 net profit rose 27.88% to 60.18 million baht, with revenue up 22.35% to 342.88 million baht. Growth came from more patients at Khun Hospital Rama 2, the heart center, and the IVF fertility unit, helped by returning Chinese clients. This shows the core business is healthy and supports the stock price.
This is the key earnings result that shows EKH's core business is growing strongly.
New specialty hospitals to drive future revenue EKH is building three new projects: Khun Wattanapat (elderly care), Bloom Hospital (mental health), and a wellness center. Bloom opened in September with 400 million baht invested, targeting 50 million baht first-year revenue. These expand EKH's revenue base and support long-term growth, pushing the stock up.
These new projects are the main growth drivers that will add revenue from Q3 2026 onward.
Q3 patient volumes rise on seasonal outbreaks EKH reported Q3 2026 patient numbers grew, with bed occupancy at 50-70%, helped by COVID-19 and flu outbreaks and volatile weather. The company expects second-half results to beat the first half and maintains double-digit full-year revenue growth. This supports the stock price.
This shows the positive trend continuing into Q3, confirming the growth story.
Brokerage sets 5.85 baht target, sees recovery Yuanta Securities maintained a Trading recommendation with a 5.85 baht target after visiting Bloom Hospital. It expects 2026 profit of 248 million baht and dividend yields of 5.5-6.1%, with a clear recovery in 2027. This gives investors confidence and can lift the stock.
Analyst coverage with a target price and dividend yield provides a valuation anchor for investors.

Latest14 Aug – 9 Oct 2026

▲4

EKH expands specialty hospitals as Q2 profit jumps 28%

Q2 profit surges 28% on higher patient volumes EKH's Q2 2026 net profit rose 27.88% to 60.18 million baht, with revenue up 22.35% to 342.88 million baht. Growth came from more patients at Khun Hospital Rama 2, the heart center, and the IVF fertility unit, helped by returning Chinese clients. This shows the core business is healthy and supports the stock price.
This is the key earnings result that shows EKH's core business is growing strongly.
New specialty hospitals to drive future revenue EKH is building three new projects: Khun Wattanapat (elderly care), Bloom Hospital (mental health), and a wellness center. Bloom opened in September with 400 million baht invested, targeting 50 million baht first-year revenue. These expand EKH's revenue base and support long-term growth, pushing the stock up.
These new projects are the main growth drivers that will add revenue from Q3 2026 onward.
Q3 patient volumes rise on seasonal outbreaks EKH reported Q3 2026 patient numbers grew, with bed occupancy at 50-70%, helped by COVID-19 and flu outbreaks and volatile weather. The company expects second-half results to beat the first half and maintains double-digit full-year revenue growth. This supports the stock price.
This shows the positive trend continuing into Q3, confirming the growth story.
Brokerage sets 5.85 baht target, sees recovery Yuanta Securities maintained a Trading recommendation with a 5.85 baht target after visiting Bloom Hospital. It expects 2026 profit of 248 million baht and dividend yields of 5.5-6.1%, with a clear recovery in 2027. This gives investors confidence and can lift the stock.
Analyst coverage with a target price and dividend yield provides a valuation anchor for investors.

Fresenius Medical Care AG & Co. KGaA (FME.XETRA)

Q3 202620 Jul – 7 Oct 2026

▲2

Fresenius Medical Care: Strong Q2, New Products, China Exit, CEO Change

Q2 profit jumps 23%, margin expands, second €1bn buyback launched Fresenius Medical Care's Q2 operating income rose 23% at constant currency, margin expanded, and EPS jumped 28%. A second €1 billion share buyback was launched after completing the first. This signals strong cash generation and management confidence, supporting the share price.
This is the core financial result that directly drives investor confidence and the stock's valuation.
New TherapyWise analytics and HDF study boost product portfolio Fresenius launched TherapyWise, a cloud analytics tool for its NxStage system, and published a study showing its hemodiafiltration (HDF) treatment cuts mortality risk by 28%. These innovations strengthen its product lineup and could drive future sales, especially as HDF expands in the U.S.
New products and clinical evidence can open new markets and increase demand for the company's treatments.
China strategy shift: exits peritoneal dialysis, takes €110m one-time charge Fresenius is refining its China business, exiting peritoneal dialysis and discontinuing the 4008A system, while focusing on advanced in-center therapies. This will cost about €110 million in one-time charges but is not expected to hurt future revenue. The move aims to improve long-term competitiveness.
The China restructuring is a significant strategic change with a near-term cost but potential long-term benefit.
CEO succession: Shervin Korangy to replace Helen Giza Fresenius named Shervin Korangy as new CEO, succeeding Helen Giza who led a €1.2 billion cost-cutting program. Leadership changes can bring fresh strategy but also uncertainty. The market will watch for continuity or shifts in direction.
A CEO change is a major event that can affect investor sentiment and future strategy.

August 202620 Jul – 7 Oct 2026

▲2

Fresenius Medical Care: Strong Q2, New Products, China Exit, CEO Change

Q2 profit jumps 23%, margin expands, second €1bn buyback launched Fresenius Medical Care's Q2 operating income rose 23% at constant currency, margin expanded, and EPS jumped 28%. A second €1 billion share buyback was launched after completing the first. This signals strong cash generation and management confidence, supporting the share price.
This is the core financial result that directly drives investor confidence and the stock's valuation.
New TherapyWise analytics and HDF study boost product portfolio Fresenius launched TherapyWise, a cloud analytics tool for its NxStage system, and published a study showing its hemodiafiltration (HDF) treatment cuts mortality risk by 28%. These innovations strengthen its product lineup and could drive future sales, especially as HDF expands in the U.S.
New products and clinical evidence can open new markets and increase demand for the company's treatments.
China strategy shift: exits peritoneal dialysis, takes €110m one-time charge Fresenius is refining its China business, exiting peritoneal dialysis and discontinuing the 4008A system, while focusing on advanced in-center therapies. This will cost about €110 million in one-time charges but is not expected to hurt future revenue. The move aims to improve long-term competitiveness.
The China restructuring is a significant strategic change with a near-term cost but potential long-term benefit.
CEO succession: Shervin Korangy to replace Helen Giza Fresenius named Shervin Korangy as new CEO, succeeding Helen Giza who led a €1.2 billion cost-cutting program. Leadership changes can bring fresh strategy but also uncertainty. The market will watch for continuity or shifts in direction.
A CEO change is a major event that can affect investor sentiment and future strategy.

Latest20 Jul – 7 Oct 2026

▲2

Fresenius Medical Care: Strong Q2, New Products, China Exit, CEO Change

Q2 profit jumps 23%, margin expands, second €1bn buyback launched Fresenius Medical Care's Q2 operating income rose 23% at constant currency, margin expanded, and EPS jumped 28%. A second €1 billion share buyback was launched after completing the first. This signals strong cash generation and management confidence, supporting the share price.
This is the core financial result that directly drives investor confidence and the stock's valuation.
New TherapyWise analytics and HDF study boost product portfolio Fresenius launched TherapyWise, a cloud analytics tool for its NxStage system, and published a study showing its hemodiafiltration (HDF) treatment cuts mortality risk by 28%. These innovations strengthen its product lineup and could drive future sales, especially as HDF expands in the U.S.
New products and clinical evidence can open new markets and increase demand for the company's treatments.
China strategy shift: exits peritoneal dialysis, takes €110m one-time charge Fresenius is refining its China business, exiting peritoneal dialysis and discontinuing the 4008A system, while focusing on advanced in-center therapies. This will cost about €110 million in one-time charges but is not expected to hurt future revenue. The move aims to improve long-term competitiveness.
The China restructuring is a significant strategic change with a near-term cost but potential long-term benefit.
CEO succession: Shervin Korangy to replace Helen Giza Fresenius named Shervin Korangy as new CEO, succeeding Helen Giza who led a €1.2 billion cost-cutting program. Leadership changes can bring fresh strategy but also uncertainty. The market will watch for continuity or shifts in direction.
A CEO change is a major event that can affect investor sentiment and future strategy.